{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:04:22Z","timestamp":1777367062170,"version":"3.51.4"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41386-026-02393-3","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:20:31Z","timestamp":1774970431000},"page":"1137-1138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to mol: Comparing apples and oranges in TRD treatment: the importance of assumptions in network meta-analysis"],"prefix":"10.1038","volume":"51","author":[{"given":"Johan","family":"Saelens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Gramser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Watzal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupert","family":"Lanzenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7144-2282","authenticated-orcid":false,"given":"Christoph","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"2393_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jad.2021.03.019","volume":"287","author":"H Li","year":"2021","unstructured":"Li H, Cui L, Li J, Liu Y, Chen Y. Comparative efficacy and acceptability of neuromodulation procedures in the treatment of treatment-resistant depression: a network meta-analysis of randomized controlled trials. J Affect Disord. 2021;287:115\u201324.","journal-title":"J Affect Disord"},{"key":"2393_CR2","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.3390\/jcm9092796","volume":"9","author":"FL Hitti","year":"2020","unstructured":"Hitti FL, Yang AI, Cristancho MA, Baltuch GH. Deep brain stimulation is effective for treatment-resistant depression: a meta-analysis and meta-regression. J Clin Med. 2020;9:2796.","journal-title":"J Clin Med"},{"key":"2393_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1080\/03007995.2016.1277201","volume":"33","author":"K Papadimitropoulou","year":"2017","unstructured":"Papadimitropoulou K, Vossen C, Karabis A, Donatti C, Kubitz N. Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. Curr Med Res Opin. 2017;33:701\u201311.","journal-title":"Curr Med Res Opin"},{"key":"2393_CR4","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905\u201317.","journal-title":"Am J Psychiatry"},{"key":"2393_CR5","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/jrsm.1454","volume":"12","author":"AL Davies","year":"2021","unstructured":"Davies AL, Galla T. Degree irregularity and rank probability bias in network meta-analysis. Res Synth Methods. 2021;12:316\u2013332.","journal-title":"Res Synth Methods"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02393-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02393-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02393-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:06:43Z","timestamp":1777363603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02393-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2393"],"URL":"https:\/\/doi.org\/10.1038\/s41386-026-02393-3","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Kraus received honoraria from Johnson & Johnson, Pfizer, LivaNova, and AbbVie. Dr. Lanzenberger received investigator-initiated research funding from Siemens Healthcare regarding clinical research using PET\/MR and travel grants and\/or conference speaker honoraria from Janssen-Cilag Pharma GmbH in 2023, and Bruker BioSpin, Shire, AstraZeneca, Lundbeck A\/S, Dr. Willmar Schwabe GmbH, Orphan Pharmaceuticals AG, Janssen-Cilag Pharma GmbH, Heel and Roche Austria GmbH., and Janssen-Cilag Pharma GmbH in the years before 2020. He is a shareholder of the start-up company BM Health GmbH, Austria, since 2019. Dr. Zarate is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2\u2009\n                      R\n                      ,6\u2009\n                      R\n                      )-hydroxynorketamine, (\n                      S\n                      )-dehydronorketamine, and other stereoisomeric dehydroxylated and hydroxylated metabolites of (\n                      R,S\n                      )-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2\u2009\n                      R\n                      ,6\u2009\n                      R\n                      )-hydroxynorketamine and (2\n                      S\n                      ,6\n                      S\n                      )-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. He has assigned his patent rights to the U.S. government, but will share a percentage of any royalties that may be received by the government. All other authors have no conflict of interest to disclose, financial or otherwise.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}